Lab
Molecular and Diagnostic Testing Labs of America
Molecular and Diagnostic Testing Labs of America was paid $157K by Medicaid between Nov 2020 and May 2023, across 49 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 15% of everything it billed.
33Billing provider infoMOLECULAR AND DIAGNOSTIC TESTING LABS OF AMERICA
TUPELO, MS 38801
TUPELO, MS 38801
33aNPI1023622305assigned 09/03/2020
33bProvider typeClinical Medical Laboratory
28Total paid$157K
24GClaims30,254
24DCodes billed49
24AFirst – last monthNov 2020 – May 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Mississippi
Rank by total paid#17 of 35
Median peer was paid$136K
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,392 | $10K | |
| 2021 | 9,328 | $41K | |
| 2022 | 12,396 | $82K | |
| 2023 | 7,138 | $25K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 15% | 4,405 | 3,203 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 14% | 5,541 | 3,750 | $22K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.5% | 551 | 276 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 8.9% | 948 | 764 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | 8.2% | 2,513 | 2,000 | $13K |
| 80061 | Lipid panel | 8.1% | 1,891 | 1,488 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | 6.9% | 1,360 | 1,049 | $11K |
| 80164 | 4.9% | 1,073 | 780 | $8K | |
| 80177 | 4.2% | 851 | 653 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.1% | 99 | 86 | $6K |
| 87150 | 4.0% | 100 | 87 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.7% | 1,020 | 650 | $4K |
37 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 73 | $2K |
| 82607 | 1.2% | 256 | $2K | |
| 80185 | <1% | 201 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 228 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 77 | $1K |
| 80076 | <1% | 178 | $992.25 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14 | $944.02 |
| 84134 | <1% | 104 | $774.68 | |
| 80165 | <1% | 72 | $633.88 | |
| 83735 | <1% | 198 | $615.79 | |
| 82947 | <1% | 208 | $603.57 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 180 | $432.90 |
| 87581 | <1% | 75 | $426.33 | |
| 87486 | <1% | 75 | $426.33 | |
| 84153 | <1% | 55 | $418.59 | |
| 83880 | <1% | 19 | $282.64 | |
| 84439 | <1% | 71 | $207.06 | |
| 81005 | <1% | 143 | $179.40 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 72 | $160.37 |
| 82746 | <1% | 15 | $119.07 | |
| 85610 | <1% | 36 | $88.78 | |
| 82728 | <1% | 13 | $73.62 | |
| 85027 | <1% | 17 | $69.84 | |
| 81000 | <1% | 23 | $57.92 | |
| 83540 | <1% | 14 | $46.56 | |
| 84132 | <1% | 15 | $29.96 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,038 | $27.07 |
| 82040 | <1% | 13 | $22.30 | |
| 81001 | <1% | 18 | $14.25 | |
| 80178 | <1% | 17 | $11.90 | |
| 84450 | <1% | 13 | $9.32 | |
| 81015 | 0% | 99 | $0.00 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 3,015 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 26 | $0.00 |
| 99072 | 0% | 182 | $0.00 | |
| 87631 | 0% | 23 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCAMPBELL, JOSEPH (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Metropolitan Cardiovascular | Irvington, NJ | $42K |
| Irwin's Pharmacy and Drug Co. INC. | Chesapeake, VA | $111.66 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.